毛皮
生物
结直肠癌
克拉斯
癌症研究
基因沉默
癌症
下调和上调
肿瘤发生
前蛋白转化酶
信号转导
大肠癌小鼠模型的建立
癌变
小发夹RNA
RNA干扰
调节器
肿瘤进展
癌细胞
转染
基因敲除
受体
免疫学
细胞生物学
作者
Yiyang Liu,Géraldine Siegfried,Simon Pernot,Zongsheng He,Marta Martín-Bórnez,Sabine Tejpar,Fanny Castanet,Grégoire Desolneux,Serge Évrard,Torsten Steinmetzer,John W.M. Creemers,Abdel‐Majid Khatib
出处
期刊:Oncogene
[Springer Nature]
日期:2026-07-12
卷期号:45 (33): 3479-3496
标识
DOI:10.1038/s41388-026-03875-w
摘要
Abstract KRAS and BRAF mutations drive colorectal cancer (CRC) progression by sustaining aberrant signaling and promoting therapeutic resistance. Here, we identify TGF-β1-COX-2 axis as a critical regulatory pathway mediated by Furin in CRC harboring KRAS or BRAF mutation. Genetic silencing or pharmacological inhibition of Furin in KRAS-mutant (KPN) and BRAF-mutant (BPN) tumor-derived cells suppressed tumor growth, reduced angiogenesis, and enhanced CD8⁺ T cell infiltration in mouse tumor models. KRAS- and BRAF-mutant organoids with impaired Furin activity exhibited increased sensitivity to 5-FU, oxaliplatin, and irinotecan. Mechanistically, Furin inhibition via shRNA or the Furin inhibitor MI1148 blocked IGF-1 receptor and TGF-β1 precursor maturation and signaling, which was associated with repressed COX-2 expression. Conversely, COX-2 over-expression elevated TGF-β1 levels, which in turn enhanced Furin expression, establishing a feed-forward loop that promoted tumor progression and angiogenesis. Moreover, Furin inhibition largely disrupted the activity of multiple kinases linked to KRAS and BRAF oncogenic signaling. In CRC patient samples, Furin expression positively correlated with KRAS, BRAF, TGF-β1, and COX-2. Collectively, these findings identify Furin as a pivotal regulator of oncogenic signaling in KRAS- and BRAF-mutant CRC, and highlight the therapeutic potential of targeting the Furin-TGF-β1-COX-2 axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI